These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28138565)

  • 1. 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.
    Surolia R; Li FJ; Wang Z; Li H; Liu G; Zhou Y; Luckhardt T; Bae S; Liu RM; Rangarajan S; de Andrade J; Thannickal VJ; Antony VB
    JCI Insight; 2017 Jan; 2(2):e91377. PubMed ID: 28138565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 6. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
    Selvaggio AS; Noble PW
    Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
    Togami K; Kanehira Y; Tada H
    Biol Pharm Bull; 2013; 36(10):1525-7. PubMed ID: 24088250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
    Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ
    Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
    Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.